Sodium Nitroprusside Injection

Product Details: Concentration: 50 mg per 2 mL (25 mg/mL) Fill Volume: Sterile Solution in a 2 mL vial Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temp]. Protect from light. Opaque sleeve included to protect the infusion solution from light Preservative free Latex free In-actives: water for injection Saleable Unit: 2 mL vial Sterile Solution Box of 1 vial NDC Number: 50 mg/2 mL (25 mg/mL) NDC 25208-003-05

View Prescribing Information

Available through MedicureDirect or Your Wholesaler

Sodium Nitroprusside Injection (NDC: 25208-003-05) can be ordered through our online ordering platform, MedicureDirect, or through your wholesaler.

Order through MedicureDirect

 

NDC: 25208-003-05

Cardinal: 5591573
McKesson: 1545342
AmerisourceBergen: 10250932

For immediate supply, Sodium Nitroprusside Injection is available as a drop shipment via Express Overnight Delivery. For assistance ordering through MedicureDirect or through working with your wholesaler, please contact our ordering department at 1-800-509-0544 or ordering@medicure.com

Important Safety Information

Indications & Usage:

Sodium nitroprusside is indicated for:

• The immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized.
• Producing controlled hypotension in order to reduce bleeding during surgery
• The treatment of acute congestive heart failure

Contraindications:

Sodium nitroprusside should not be used:

• In the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting
• To produce hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) coming to emergency surgery
• In patients with congenital (Leber's) optic atrophy or with tobacco amblyopia
• For the treatment of acute congestive heart failure associated with reduced peripheral vascular resistance

Precautions:

• General: Can cause increases in intracranial pressure. Use with extreme caution in patients whose intracranial pressure is already elevated.
• Hepatic: Patients with hepatic insufficiency are more susceptible to cyanide toxicity; use caution.
• Use in Anesthesia: If possible, correct pre-existing anemia and hypovolemia prior to administration when sodium nitroprusside is used for controlled hypotension during anesthesia. Hypotensive anesthetic techniques may also cause abnormalities of the pulmonary ventilation/perfusion ratio; patients intolerant of these abnormalities may require a higher fraction of inspired oxygen. Use extreme caution in patients who are poor surgical risks (A.S.A. Class 4 and 4E).
• Lab Tests: The cyanide-level assay is technically difficult and cyanide levels in body fluids other than packed red blood cells are difficult to interpret. Cyanide toxicity will lead to lactic acidosis and venous hyperoxemia, but these findings may not be present until an hour or more after the cyanide capacity of the body's red-cell mass has been exhausted.
• Drug Interactions: The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
• Pregnancy: Use during pregnancy only when there is no appropriate alternative for a particular patient as cyanide toxicity may be fatal to the fetus.
• Nursing Mothers: No information about the presence of sodium nitroprusside in human milk, the effects on the breastfed infant, or the effects on milk production.

Adverse Reactions:

Excessive hypotension, cyanide toxicity, methemoglobinemia, thiocyanate toxicity, bradycardia, electrocardiographic changes, tachycardia, rash, hypothyroidism, ileus, decreased platelet aggregation, increased intracranial pressure, flushing, venous streaking and irritation at the infusion site.

Overdosage:

Overdosage of nitroprusside can be manifested as excessive hypotension, cyanide toxicity, or thiocyanate toxicity. Reasonable suspicion of cyanide toxicity is grounds for initiation of treatment; results of laboratory tests should not be awaited. Refer to Prescribing Information for information on the treatment of cyanide toxicity.

See Full Prescribing Information, including WARNINGS on excessive hypotension and cyanide toxicity.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.